HealthCare Royalty Partners
HealthCare Royalty (HCRx) is an asset-focused investor that acquires royalties and provides corporate financing to commercial or near-commercial stage biopharmaceutical products. The firm structures royalty monetizations and debt-based financing solutions to provide non-dilutive, long-term capital to biopharma companies and has invested over $5 billion across more than 85 products. HCRx maintains offices in the New York metro area, San Francisco, Boston, Miami and London and employs a multidisciplinary team of industry executives, scientists, physicians, bankers and advisors.
HealthCare Royalty Partners
Stamford, Connecticut, United States, North America
Services
Royalty Monetization
Acquisition of product-level royalties or future revenue streams from marketed or near-commercial biopharmaceutical products to provide upfront, non-dilutive capital.
Corporate Financing (Debt and Structured Capital)
Custom debt and structured financing solutions including senior debt, senior secured notes, limited recourse loans, structured credit and similar instruments to strengthen balance sheets or fund growth.
Synthetic Royalty™ Financing
Financing structures that combine elements of royalty monetization and debt to provide contingent or revenue-linked funding.
Royalty Bonds and Royalty Notes
Issuance or purchase of structured instruments backed by product royalties (e.g., royalty bonds, royalty notes) to fund portfolio transactions.
Royalty Monetization
Acquisition of product-level royalties or future revenue streams from marketed or near-commercial biopharmaceutical products to provide upfront, non-dilutive capital.
Corporate Financing (Debt and Structured Capital)
Custom debt and structured financing solutions including senior debt, senior secured notes, limited recourse loans, structured credit and similar instruments to strengthen balance sheets or fund growth.
Synthetic Royalty™ Financing
Financing structures that combine elements of royalty monetization and debt to provide contingent or revenue-linked funding.
Royalty Bonds and Royalty Notes
Issuance or purchase of structured instruments backed by product royalties (e.g., royalty bonds, royalty notes) to fund portfolio transactions.
Portfolio
Royalty monetization up to €185 million; Jan 2025
#Pharmaceuticals / Biopharmaceuticals
Royalty monetization up to $115 million; Mar 2024
#Biopharmaceuticals
Royalty monetization up to $40 million; Nov 2023
#Pharmaceuticals
Royalty monetization up to $110 million; Aug 2023
#Pharmaceuticals
Royalty monetization up to €185 million; Jan 2025
#Pharmaceuticals / Biopharmaceuticals
Royalty monetization up to $115 million; Mar 2024
#Biopharmaceuticals
Royalty monetization up to $40 million; Nov 2023
#Pharmaceuticals
Royalty monetization up to $110 million; Aug 2023
#Pharmaceuticals